← FDA DRUG APPROVALS

FDA ANDA · ANDA217685

DOXYCYCLINE HYCLATE

Sponsor: SLATE RUN PHARMA

APPLICATION
ANDA217685
TYPE
ANDA
ORIGINAL APPROVAL
2024-06-21
LATEST ACTION
2025-03-31
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

DOXYCYCLINE HYCLATEPrescription
DOXYCYCLINE HYCLATE EQ 200MG BASE/VIAL · INJECTABLE · INJECTION
DOXYCYCLINE HYCLATEPrescription
DOXYCYCLINE HYCLATE EQ 100MG BASE/VIAL · INJECTABLE · INJECTION

Approval history

2025-03-31Labeling · Supplement 1 · standardAP
2024-06-21UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →